Markets
UBER
(Sebastian Gollnow/Picture Alliance via Getty Images)
Vroom

Tesla’s pain seems to be Uber’s gain

Uber has been strong out of the gate in 2025, with Goldman Sachs adding the taxi company to its “conviction list” of stocks to own on Tuesday.

Matt Phillips

Ride-hailing app Uber is seeing its second straight day of strong gains, in early trading, with a catalyst apparently being the addition of the company to Goldman Sachs’ “conviction list” of stocks to own in 2025.

The Fly reports:

“The firm sees scaling end markets, rising profitability levels, and increased evidence of the platform cross-sell and ‘flywheel’ effects driving a sustained mix of growth, margins and free cash flow for Uber. Goldman has a Buy rating on the shares with a $96 price target.”

Uber is in an interesting spot. After an underwhelming 2024, in which its shares slipped 2% and badly underperformed the 23% gain in the S&P 500, it seems investors are taking a second look at the company, which could benefit from any eventual autonomous-driving revolution, while at the same time generating real and growing profits now. (That’s a key difference from Tesla’s still largely theoretical Cybercab business, which is supposedly a key driver of Tesla sentiment of late.)

In fact, recently there’s been a bit of a divergence between the performance of Uber and Tesla shares, with a more negative correlation between the two — that is, when one goes up, the other goes down — than we’ve ever seen before. That might suggest that some investors see less of a threat of tech takeover of Uber’s key business from Tesla as it struggles to turn its self-driving taxi ambitions into a reality.

More Markets

See all Markets
markets

Spectrum-owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its full-year revenue per user guidance.

“It'll be close either way in terms of whether we end up with net growth,” said Fischer.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.